aap Implantate H1 FY26 EBITDA loss narrows to EUR 140,000; revenue falls 5% to EUR 6 million

• aap Implantate posted H1 2026 revenue of EUR 6 million, down 5% year over year, as Middle East outages weighed.
• EBITDA loss narrowed to EUR 100,000 from EUR 300,000, driven by a higher gross margin and an optimized cost structure.
• Gross margin rose to 90% from 85%, while operating loss was steady at EUR 1 million.
• Trauma segment EBITDA more than doubled to EUR 163,000, while Silver segment EBITDA loss narrowed to EUR 303,000.
• Management cited record order intake in July, FDA clearance for the LOQTEQ VA Proximal Humerus System, and reiterated earnings guidance mid-range.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. aap Implantate AG published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2384244_en) on August 18, 2026, and is solely responsible for the information contained therein.